Tag: the war on (some) drugs

Were Plato and Dante munching on magic mushrooms? Probably

Dr Bill Richards looks at me with kind eyes through the computer screen, his face framed by an overgrown plant, bookshelves and an abstract painting. It hangs behind him in shades of blue, yellow and red, the colours fluid and swirling yet handsomely encased in shapes that have no clear name. If that sounds akin to a psychedelic experience, you’re in luck: because Bill and I are sitting down to discuss just that.

Not one experience in particular, but hundreds of them. Hundreds which Bill has studied in his career as a leader in the field of psychedelic research. He was one of the first to explore psychedelics’ potential for treating addiction as well as end of life anxiety among terminal cancer patients. His passion for this subject began in Germany in 1963 and was nurtured under the tutelage of psychologist Abraham Maslow and the psychiatrist Hanscarl Leuner. He returned to the US to carry out psychotherapy research with psychedelics from 1967 to 1977; then, at the height of the War on Drugs, he had to shut things down.

He had by then already made waves in the field, notably with his seminal articl – Implications of LSD and Experimental Mysticism – co-authored overnight in 1966 with Walter Pahnke and mailed off at sunrise. 

Today, Bill has an academic appointment in the psychiatry department of the Johns Hopkins School of Medicine, where he led a study in 2016 on how psilocybin could be used among cancer patients to alleviate depression. It was described as “the most rigorous controlled trial of psilocybin to date”. He appeared in Michael Pollan’s 2022 documentary, How To Change Your Mind, and his much-lauded book, Sacred Knowledge: Psychedelics and Religious Experiences, is out in Spanish this May.

Bill is a rare breed in the field of psychedelics in that he straddles both scientific and spiritual sides of the discipline. What’s more, he believes the dichotomy that separates the two is false. “It’s not either-or,” he quips. For Bill, it would be remiss to discuss psychedelics in purely scientific terms, just as it would be reductive to explore only their spiritual dimension.

Alongside his psychology credentials, Bill holds a Master of Divinity from Yale (at which point he wished to become a minister) and a PhD from The Catholic University of America. “I grew up with a father who taught chemistry, physics and geology, and a rather pious mother — so science and religion have always been in my blood,” he says. Today still, he plays the organ in his local Episcopal Church. This dual influence has profoundly impacted Bill — whose ideas, out of all those I have heard, I find to be the most inspirational. The mystical experience induced by psilocybin or ayahuasca is, according to him, not caused by the drugs at all. Rather, these substances unlock what is already in our mind. Religious mystics, Bill argues, can access such states of consciousness without the help of psychoactive compounds.

These “transcendental states of consciousness” defy our categories of thinking about “time and space”. “Sometimes,” Bill adds, “it seems more the realm of philosophy than of science.” Some might perceive such a statement as invalidating the scientific relevance of psychedelics; but that is not Bill’s intention. “These drugs,” he says, have likely been around since the dawn of civilisation. They “emerge in cultures” and then “get suppressed”. We have lost touch with historic knowledge, with wisdom that used to be passed down among our ancestors. “Plato and Dante were writing out of mystical states of consciousness,” Bill claims. “But whether they were natural mystics or were munching on magic mushrooms, I have no idea.”

Keep reading

Single LSD dose provides lasting anxiety relief: Research

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to an LSD formula to treat generalized anxiety disorder after an initial study has shown that a single dose of the drug could provide lasting relief.

The LSD therapy developed by Mind Medicine Inc. (MindMed) must still go through the standard FDA approval process and will soon enter Phase 3 clinical trials.

The study that prompted FDA advancement found the drug was “generally well-tolerated with most adverse events rated as mild to moderate, transient and occurring on dosing day, and being consistent with expected acute effects of the study drug,” according to a release on the findings.

The most common adverse effects on the initial “dosing day” — or when patients were first given the drug — included hallucinations, euphoric mood, abnormal thinking, headache, dizziness and nausea, among others.

The company plans to meet for an update with the FDA in the coming months and begin an expanded clinical program in the second half of the year.

MindMed, a pharmaceutical company focused on developing psychedelic drugs into medicines, has spent years researching possible medicinal uses for LSD, an illicit drug that has never been approved for medicinal use. The specific LSD formula from the study is dubbed MM120.

Keep reading

Florida Lawmakers Pass Bill To Restrict Hemp Products And Ban Delta-8 THC, Sending It To DeSantis’s Desk

The Florida Legislature has approved a bill to regulate hemp-derived products in the state and eliminate delta-8 THC, which is banned in 17 states and severely restricted in seven more—though it is a popular item sold in retail establishments and people have used it for chronic illnesses.

Both chambers approved the legislation on Wednesday.

The Florida Senate passed the measure (SB 1698), sponsored by Polk County Republican Colleen Burton, unanimously, 39-0. That vote came just a few hours after a more contested vote in the House, where it was approved on a 64-48 vote.

For the past two years, the Legislature has worked on attempting to regulate the amount of THC in hemp-derived products. THC is the main component in cannabis that provides the psychoactive or “high” effect. The measure also bans the sale of all delta-8 products, one of the most popular items sold in retail establishments throughout the state over the past four years. And it also prohibits businesses from possessing hemp extract products that are considered “attractive” to children.

The measure says that the THC cannot exceed 5 milligrams per serving or 50 milligrams per package. Burton and the sponsor of the measure in the House, Manatee County’s Tommy Gregory, had originally set the limits at 2 milligrams per serving and 10 milligrams per package, but Gregory amended the limits earlier this week after taking input from the hemp industry.

Yet many of those who work in the hemp business in Florida say that those slightly increased THC caps are not going to be sufficient in terms of sustaining their economic vitality.

Keep reading

UN Body Reaffirms That Marijuana Legalization Violates International Treaties, While Addressing Germany Cannabis Reform And U.S. Psychedelics Movement

The United Nations’s (UN) drug control body is reiterating that it considers legalizing marijuana for non-medical or scientific purposes a violation of international treaties, though it also said it appreciates that Germany’s government scaled back its cannabis plan ahead of a recent vote. The global narcotics agency is also taking note of the psychedelics policy reform movement in U.S. states.

This is mostly par for the course for the International Narcotics Control Board (INCB), which has routinely criticized countries for allowing the enactment of cannabis legalization due to their obligations under various Single Convention treaties going back to 1961. But as Germany entered the fold, and the U.S. has continued to move toward marijuana and psychedelics reform, the body is again making its disappointment known.

INCB’s 2023 annual report, which was published on Tuesday, “underscores” that member nations are required to “take such legislative and administrative measures as may be necessary” to criminalize “the production, manufacture, export, import, distribution of, trade in, use and possession of drugs” such as marijuana under decades-old treaty agreements.

“The Board continues to reiterate its concern regarding the legalization of the use of cannabis for non-medical and non-scientific purposes in several jurisdictions, with other jurisdictions considering similar action,” it said.

To that point, INCB also included a recommendation in the latest report to recall an analysis from its 2022 report that, at one point, suggested that the U.S. is out of compliance with drug treaty obligations because the federal government is passively allowing states within the country to legalize marijuana.

“The apparent tension between these provisions and the trend towards legalization must be addressed by the signatories to the three drug control conventions,” it said.

Keep reading

Cocaine use doubles in NZ: ‘A big change in a short space of time’

Cocaine consumption in New Zealand has almost doubled – although use is still very low – a new report has found.

The Drug Foundation’s latest study uses wastewater testing, as well as the national health and drug trends surveys, to paint a picture of illicit drug use in New Zealand.

Executive director Sarah Helm said 56,000 people (1.3 percent) used cocaine in the 2022/2023 year, which is a 93 percent increase on the previous three years’ average.

But she said that number was relatively small compared to other countries.

“We have a very low base and compared to international cocaine use it’s very, very low. However, that is a big change in a relatively short space of time.”

Helm said drug use in New Zealand reflected what was available and a bump in cocaine use could signal an influx from overseas.

“We know from international information from the UN and others that the international production of cocaine has significantly increased. They’re looking for new markets and trying to break into markets where there hasn’t been a lot of cocaine consumption previously.”

She said there have been a number of recent record cocaine busts by police and NZ Customs, but that had not eliminated supply.

Keep reading

GOP Senators Push For Federal And State Response To Indian Tribe’s 4/20 Marijuana Sales Plan In North Carolina

Two Republican senators are asking federal, state and local officials what steps they are taking to enforce marijuana prohibition as an Indian tribe prepares to launch recreational cannabis sales on its lands within North Carolina on April 20.

On Friday, Sens. Thom Tillis (R-NC) and Ted Budd (R-NC) sent a letter with 19 questions about their concerns regarding the Eastern Band of Cherokee Indians (ECBI) marijuana plan to the U.S. attorney general, Drug Enforcement Administration (DEA), Department of Interior (DOI), Financial Crimes Enforcement Network (FinCEN), National Indian Gaming Commission and various North Carolina state and local law enforcement agencies.

“As our nation is facing an unprecedented drug crisis that is harming our communities, it is vital to learn what measures your departments and agencies are taking to uphold current federal and state laws,” they wrote, adding that the “matter raises multiple questions on how North Carolina communities will be kept safe.”

ECBI members approved a referendum last September to legalize adult-use cannabis, becoming the first jurisdiction within the borders of North Carolina to enact the reform. More recently, last week the tribe announced that it had set a target date to open retail sales: April 20, 2024, also known as 4/20.

This follows ECBI’s 2021 move to legalize medical cannabis and register Qualla Boundary LLC to dispense marijuana to patients. Registration for the program opened to all North Carolina residents this past June, and in October, the tribe issued its first round of medical marijuana cards.

“With unclear guidance, it makes it difficult for state and local officials to uphold  the rule of law in our communities,” the senators wrote in their letter. “In particular, we have the responsibility to ensure our youth are shielded from untested marijuana products being produced and sold by Qualla Enterprise LLC.”

Tillis and Budd then listed 19 questions that they’re asking officials to respond to, depending on their jurisdiction.

That includes queries about whether tribes are considered exempt from the Controlled Substances Act (CSA), whether agencies have concerns about the potential cannabis shop will attract transnational criminal enterprises, whether tribes can take land into trust for the purposes of selling cannabis and whether financial institutions can provide loans and credit to tribes seeking to open a marijuana business.

The senators are also pressing for answers on whether federal officials allow gaming profits derived from casinos to be used in support of marijuana ventures.

Ahead of last year’s legalization vote, Qualla Enterprises published an op-ed in the tribal newspaper, Cherokee One Feather, championing the benefits of adult-use sales. It compared the opportunity to when, “thirty years ago, the Cherokee People decided to build a casino.”

“This was highly controversial at the time, in part because nowhere in the surrounding region allowed gaming,” the company said at the time. “But we were not afraid to be different. Harrah’s Cherokee Casino has benefited this Tribe and its members in more ways than we ever imagined.”

The bulk of new jobs created by the policy change, according to the company, would be filled by enrolled ECBI members. In the medical system as of last year, 84 percent of cultivation employees were tribal members, its op-ed said, “which represents the highest of any business owned by the tribe.”

The op-ed also pointed to a statewide poll that found 73 percent of North Carolina residents support legal medical marijuana. And it cited estimates suggesting the state’s illicit cannabis activity amounted to nearly $3.2 billion in 2022.

A more recent survey of North Carolinians, conducted by the Meredith Poll and published last month, found 78 percent support for lawmakers to pass a medical marijuana bill this year.

The tribe’s moves to legalize despite North Carolina’s ongoing prohibition of marijuana drew criticism from other politicians, including Rep. Chuck Edwards (R-NC). Ahead of the election, Edwards, who is not Native, authored an op-ed in Cherokee One Feather warning that legalization on the tribal land “would be irresponsible, and I intend to stop it.”

The congressman also filed a bill in the U.S. House that would slash a portion of federal funding from tribes and states that legalize marijuana.

Then-Principal Chief Richard G. Sneed called the move “a big misstep” at the time. He told Marijuana Moment that he believed pushback from Edwards and others may have emboldened tribal members to support the measure.

“The worst thing that a non-Indian elected official can do is tell a sovereign, federally-recognized Indian tribe how they ought to handle their business,” Sneed said in an interview.

Keep reading

Oregon Legislators Overwhelmingly Vote To Recriminalize Low-Level Drug Possession

Oregon legislators last week overwhelmingly approved recriminalization of low-level drug possession, reversing a landmark reform that voters endorsed when they passed Measure 110 in 2020. Gov. Tina Kotek has indicated that she is inclined to sign the bill, ratifying a regression driven by unrealistic expectations and unproven assertions.

“With this bill,” Senate Majority Leader Kate Lieber (D–Portland) claims, “we are doubling down on our commitment to make sure Oregonians have access to the treatment and care that they need.” But Oregon is not merely making sure that people “have access” to treatment; it is foisting “help” on people who do not want it by threatening them with incarceration.

H.B. 4002 makes drug possession a misdemeanor punishable by up to six months in jail. A defendant can avoid that outcome by enrolling in a treatment program.

Under Measure 110, by contrast, drug possession became a Class E violation punishable by a $100 fine. Drug users could avoid the fine by completing a “health assessment” at an “addiction recovery center.” The initiative said the assessment should “prioritize the self-identified needs of the client” and refer him to appropriate services. But Measure 110 did not make agreement to those services mandatory.

The initiative’s supporters argued that coercive treatment is both less effective and more ethically problematic than voluntary treatment. “Research suggests that, except in certain circumstances where drug users are uniquely self‐​motivated (such as doctors and commercial airline pilots who fear losing their licenses), coercive treatment is futile at best and may increase the likelihood of overdose in people who relapse after release from treatment,” Jeffrey Singer notes in a Cato Institute blog post.

The policy embodied by H.B. 4002 is notably different from the legal approach to alcohol abusers, who generally cannot be forced into treatment unless they commit crimes such as driving while intoxicated. Measure 110’s supporters argued that abuse of those substances likewise should be treated as a health issue rather than a criminal matter.

Over 58 percent of voters agreed. But a continuing increase in opioid-related deaths, coupled with nuisances related to public drug use, soured Oregonians on Measure 110. By last August, at which point the initiative had been in effect for only a year and a half, an Emerson College poll found that 64 percent of Oregon voters favored reinstating criminal penalties for possession.

Keep reading

Vermont Lawmakers Consider Removing Psilocybin Legalization Provision From Psychedelic Study Group Bill

A Vermont legislative panel continued its consideration on Thursday of a bill that would legalize psilocybin in the state and establish a work group on how to further regulate psychedelics for therapeutic use.

Though members of the Senate Health and Welfare Committee took no formal action on the measure, S. 114, they heard invited testimony and signaled their openness to making a number of changes to the underlying proposal—including removing the legalization portion and instead making that an issue for the work group to study.

“It could be that decriminalization is going to get in the way of therapeutic use,” said Sen. Ginny Lyons (D), the committee chair. “What we’re looking for is the value of therapeutic use.”

Other possible changes to the bill raised by lawmakers during the hearing included adjusting the membership of the work group, for example to remove members of the legislature and add a representative from the University of Vermont Medical School—something Lyons suggested during the committee’s initial consideration of the bill last month.

Additional members of the panel would include representatives from Johns Hopkins University School of Medicine, the state Office of Professional Regulation and the advocacy group Decriminalize Nature.

Keep reading

Iowa vaping bill draws opponents from retailers, health care groups

An Iowa bill that would add requirements to manufacturers of vaping and e-cigarette products has two surprising allies standing together in opposition: vape shops and health care organizations.

House Bill 682 and its companion legislation, Senate File 2402, would require vaping manufacturers who sell products in the state to include them on a new registry. The registration fee is $100 per product. Retailers could only sell products listed on the registry.

David Scott of Altria, a manufacturer of tobacco and related products, said the bill does not prohibit the sale of any legal product. What the bill does is prevent illegal products from overseas.

“China have over 50% of the (products) that are illegal,” Scott told a House Ways and Means subcommittee this week. “Three out of the five youth brands are illicit but they are still being brought in.”

The Food and Drug Administration created a similar registry on the federal level. In January, the 5th U.S. Circuit Court of Appeals ruled that the FDA’s decisions were made arbitrarily and capriciously and that the agency should reconsider its guidelines. Scott said the FDA admits it doesn’t have the resources to monitor the products.

“If you are not on the directory, the FDA has no idea what the ingredients are in your vape,” Scott said. “They have no control of your marketing and we have no idea of the manufacturing process.

Iowa is one of 23 states considering bills that would require a vaping product registry, according to Consumer Advocates for Smoke-free Alternatives Association, an organization opposing the bills.

Sarah Linden, owner of Generation V in Council Bluffs and Davenport, told the subcommittee that the bill would put a strain on her business.

“It would eliminate 99% of the vapor products on the market,” Linden said. Retailers said vape users will find other ways to get their product if it is unavailable in their stores.

Retailers have an unlikely ally in health care organizations. The American Cancer Society is listed as “against the bill” in lobbyist declarations. The American Heart Association is undecided. CAFE Iowa Citizens Action Network, an organization that advocates for tobacco control policies to reduce its use, is also against the bill.

Keep reading

New Jersey Bill Would Force Drivers Suspected Of Being High On Marijuana To Provide A Blood Sample To Police

Cannabis experts are concerned about a lawmaker’s attempt to require motorists suspected of driving under the influence of marijuana to provide a blood sample to police.

Critics of the recently introduced bill say it would not only give police more power that would likely be wielded disproportionately against people of color, but they also argue the testing methods called for in the bill don’t even work.

Joshua Bachner, a cannabis attorney at law firm Mandelbaum Barrett, criticized the move as an example of government overreach.

“The state should develop—and there’s many of us in the state happy to coordinate with them—a comprehensive, reliable method for determining impairment,” he said. “But these piecemeal approaches are only going to cause a lot of victimization, frankly, for those who are falsely accused.”

Under current law, anyone in New Jersey who drives is consenting to provide a breath sample if police believe they are driving drunk—it’s called “implied consent.” The new bill would expand that to include a blood test and apply to any narcotic, hallucinogenic or other drug. Someone would be deemed under the influence of marijuana if they test positive for 3 nanograms or more of THC—the chemical that gets cannabis users high.

The push to expand implied consent laws to apply to drivers suspected of marijuana use comes two years after New Jersey’s recreational marijuana market launched, and as legal cannabis becomes more prevalent nationwide.

Keep reading